1-20 of 49
Peter Sportelli
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase II Trial of Acalabrutinib in Combination with PI3Kδ Inhibitor Umbralisib and the Anti-CD20 Antibody Ublituximab (AU2) in Patients with Previously Untreated Mantle Cell Lymphoma (MCL)

Alexey V Danilov, Alexandra Muir, Ivana Melgar, Sandrine Puverel, Peter Sportelli, Hari P. Miskin, Lu Chen, Geoffrey Shouse
Journal: Blood
Blood (2022) 140 (Supplement 1): 3633–3634.
https://doi.org/10.1182/blood-2022-159805
Published: 2022
Journal Articles

First-in-Human (FIH) Study of the Fully-Human Kappa-Lambda CD19/CD47 Bispecific Antibody TG-1801 in Patients (pts) with B-Cell Lymphoma

Eliza Hawkes, Katharine L. Lewis, Nicole Wong Doo, Sushrut S. Patil, Hari P. Miskin, Peter Sportelli, Kathryn S. Kolibaba, Emmanuel Normant, Tejasvi Turpuseema, Chan Y. Cheah
Journal: Blood
Blood (2022) 140 (Supplement 1): 6599–6601.
https://doi.org/10.1182/blood-2022-169171
Published: 2022
Journal Articles

The Combination of Umbralisib Plus Ublituximab Is Active in Patients with Relapsed or Refractory Marginal Zone Lymphoma (MZL): Results from the Phase 2 Global Unity-NHL Trial

Julio C. Chavez, Neta Goldschmidt, Felipe Samaniego, Tomasz Wrobel, Federica Cavallo, Gustavo Fonseca, Sung-Soo Yoon, Lubos Drgona, Eliza Hawkes, Itai Levi, Hari P. Miskin, Peter Sportelli, Owen A. O'Connor, Nathan H. Fowler, Pier Luigi Zinzani
Journal: Blood
Blood (2021) 138 (Supplement 1): 45.
https://doi.org/10.1182/blood-2021-147425
Published: 2021
Journal Articles

Efficacy and Safety of Umbralisib, Ublituximab (U2), and U2 Plus Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

John M. Burke, Gustavo Fonseca, Wojciech Jurczak, Jason Melear, Miguel Islas-Ohlmayer, James A Reeves, Parameswaran Venugopal, Tomasz Wróbel, Don Stevens, John M. Pagel, Jerome Goldschmidt, Hari P. Miskin, Peter Sportelli, Owen A. O'Connor, Nilanjan Ghosh
Journal: Blood
Blood (2021) 138 (Supplement 1): 527.
https://doi.org/10.1182/blood-2021-151054
Published: 2021
Journal Articles

Efficacy and Safety of Ublituximab in Combination with Umbralisib (U2) in Patients with Chronic Lymphocytic Leukemia (CLL) By Treatment Status: A Sub-Analysis of the Phase 3 Unity-CLL Study

Ryan Jacobs, Wojciech Jurczak, Ian W. Flinn, Sebastian Grosicki, Krzysztof Giannopoulos, Tomasz Wróbel, Syed F. Zafar, Jennifer L. Cultrera, Suman Kambhampati, Alexey V. Danilov, John M. Burke, Jerome Goldschmidt, Douglas F. Beach, Scott F. Huntington, Javier Pinilla Ibarz, Jeff P. Sharman, Tanya Siddiqi, Danielle M. Brander, Mazyar Shadman, John M. Pagel, Monika Dlugosz-Danecka, Nilanjan Ghosh, Kathryn S. Kolibaba, Peter Sportelli, Hari P. Miskin, Owen A. O'Connor, Michael S. Weiss, John G. Gribben
Journal: Blood
Blood (2021) 138 (Supplement 1): 3726.
https://doi.org/10.1182/blood-2021-147460
Published: 2021
Journal Articles

Favorable Outcomes for Patients Treated with U2 with Co-Morbidities or Concomitant Medications: A Retrospective Analysis of Unity-CLL Phase 3 Trial

Javier Pinilla Ibarz, Wojciech Jurczak, Suman Kambhampati, Ewa Lech Maranda, Tomasz Wróbel, Jeff P. Sharman, Syed F. Zafar, Marc Hoffmann, Scott F. Huntington, Ryan Jacobs, Osnat Bairey, Chris Rowland, Hari P. Miskin, Peter Sportelli, Michael S. Weiss, Owen A. O'Connor, Ian W. Flinn
Journal: Blood
Blood (2021) 138 (Supplement 1): 3748.
https://doi.org/10.1182/blood-2021-151292
Published: 2021
Journal Articles

A Phase 2 Study Evaluating the Addition of Ublituximab and Umbralisib (U2) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL): A Minimal Residual Disease (MRD)-Driven, Time-Limited Approach

Lindsey E. Roeker, Lori A. Leslie, Jake D. Soumerai, Victoria Falco, Gail Panton, Andrew D. Zelenetz, Lorenzo Falchi, Jae H Park, Camila Pena-Velasquez, Sonia Lebowitz, Kristen Battiato, Carissa Laudati, Meghan C. Thompson, David J. Straus, Yehudit Fox, Elizabeth McCarthy, Sabrina Kdiry, Rosalba Martignetti, Hari P. Miskin, Peter Sportelli, Anthony R. Mato
Journal: Blood
Blood (2021) 138 (Supplement 1): 395.
https://doi.org/10.1182/blood-2021-146999
Published: 2021
Journal Articles

Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy

Clinical Trials & Observations
Anthony R. Mato, Nilanjan Ghosh, Stephen J. Schuster, Nicole Lamanna, John M. Pagel, Ian W. Flinn, Jacqueline C. Barrientos, Kanti R. Rai, James A. Reeves, Bruce D. Cheson, Paul M. Barr, Suman Kambhampati, Frederick Lansigan, Jeffrey J. Pu, Alan P. Skarbnik, Lindsey Roeker, Gustavo A. Fonseca, Andrea Sitlinger, Issam S. Hamadeh, Colleen Dorsey, Nicole LaRatta, Hanna Weissbrot, Eline T. Luning Prak, Patricia Tsao, Dana Paskalis, Peter Sportelli, Hari P. Miskin, Michael S. Weiss, Jakub Svoboda, Danielle M. Brander
Journal: Blood
Blood (2021) 137 (20): 2817–2826.
https://doi.org/10.1182/blood.2020007376
Published: 2021
Includes: Supplemental data
Journal Articles

Umbralisib, the Once Daily Dual Inhibitor of PI3Kδ and Casein Kinase-1ε Demonstrates Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: Results from the Phase 2 Global Unity-NHL Trial

Pier Luigi Zinzani, MD, Felipe Samaniego, MD, Wojciech Jurczak, MD PhD, Nilanjan Ghosh, MD PhD, Enrico Derenzini, MD PhD, James A Reeves, MD, Wanda Knopinska-Posluszny, MD PhD, Chan Yoon Cheah, MBBS, Tycel J. Phillips, MD, Ewa Lech-Marańda, MD PhD, Bruce D. Cheson, MD, Paolo F Caimi, MD, Sebastian Grosicki, MD PhD, Lori A. Leslie, MD, Julio C. Chavez, MD, Gustavo A. Fonseca, MD, Sunil Babu, Daniel J. Hodson, MDPhD, Spencer H. Shao, MD, John M. Burke, MD, Jeff P Sharman, MD, Jennie Y. Law, MD, John M. Pagel, MDPhD, Owen A. O'Connor, MD PhD, Hari P. Miskin, MSc, Peter Sportelli, BS, Michael S. Weiss, Nathan H Fowler, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 34–35.
https://doi.org/10.1182/blood-2020-134851
Published: 2020
Journal Articles

Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study

John G. Gribben, MD DSc, FRCP, FRCPath, FMedSci, Wojciech Jurczak, MD PhD, Ryan W. Jacobs, MD, Sebastian Grosicki, MD PhD, Krzysztof Giannopoulos, MD PhD, Tomasz Wrobel, MDPhD, Syed F. Zafar, MD, Jennifer L. Cultrera, MD, Suman Kambhampati, MD, Alexey Danilov, MD, John M. Burke, MD, Jerome Goldschmidt, MD, Douglas F. Beach, MD, Scott F. Huntington, MD MPH, Javier Pinilla Ibarz, MD PhD, Jeff P Sharman, MD, Tanya Siddiqi, MD, Danielle M. Brander, MD, John M. Pagel, MDPhD, Kathryn S. Kolibaba, MD, Monika Dlugosz-Danecka, MD PhD, Nilanjan Ghosh, MD PhD, Peter Sportelli, BS, Hari P. Miskin, MSc, Owen A. O'Connor, MD PhD, Michael S. Weiss, Ian W. Flinn, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 37–39.
https://doi.org/10.1182/blood-2020-134783
Published: 2020
Journal Articles

A Phase 1/2 Study of Umbralisib, Ublituximab, and Venetoclax (U2-Ven) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Paul M. Barr, MD, Shuo Ma, MD PhD, Clive S. Zent, MD, Andrea M. Baran, MS, Andrew Bui, Philip J Meacham, PhD, Ashley Morrison, RN, Kelsey Holkovic, RN, Jane L. Liesveld, MD, Deborah A Mulford, MD, Peter Sportelli, BS, Hari P. Miskin, MSc, Michael S. Weiss, Jonathan W. Friedberg, MD MSSc, Brian T. Hill, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 41–42.
https://doi.org/10.1182/blood-2020-134818
Published: 2020
Journal Articles

Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia

Clinical Trials & Observations
Matthew Lunning, Julie Vose, Loretta Nastoupil, Nathan Fowler, Jan A. Burger, William G. Wierda, Marshall T. Schreeder, Tanya Siddiqi, Christopher R. Flowers, Jonathon B. Cohen, Peter Sportelli, Hari P. Miskin, Michael S. Weiss, Susan O’Brien
Journal: Blood
Blood (2019) 134 (21): 1811–1820.
https://doi.org/10.1182/blood.2019002118
Published: 2019
Includes: Supplemental data
Journal Articles

A Phase 1/2 Study of Umbralisib Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Paul M. Barr, MD, Brian T. Hill, MD, Shuo Ma, MD PhD, Andrea M Baran, MS, Andrew Bui, Philip J Meacham, MS, Ashley Morrison, Jane L. Liesveld, MD, Deborah A Mulford, MD, Peter Sportelli, BS, Hari P Miskin, MSc, Michael S Weiss, Jonathan W. Friedberg, MD, Clive S Zent, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 360.
https://doi.org/10.1182/blood-2019-123404
Published: 2019
Journal Articles

Combination of Umbralisib, Ublituximab, and Bendamustine Is Safe and Highly Active in Patients with Advanced Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

Matthew A. Lunning, DO, Philip Bierman, MD, R. Gregory Bociek, MD, Marshall T. Schreeder, MD, Tanya Siddiqi, MD, Christopher R Flowers, MD MS, Jonathon B. Cohen, MD MS, Susan Blumel, RN, Kathy Cutter, RN, Emily K. Pauli, BMBS,PharmD, Peter Sportelli, BS, Hari P Miskin, MSc, Michael S. Weiss, Julie M. Vose, MD MBA
Journal: Blood
Blood (2018) 132 (Supplement 1): 4197.
https://doi.org/10.1182/blood-2018-99-118917
Published: 2018
Journal Articles

Phase I/II Study of Umbralisib (TGR-1202) in Combination with Ublituximab (TG-1101) and Pembrolizumab in Patients with Relapsed/Refractory CLL and Richter's Transformation

Anthony R. Mato, MDMSCE, Jakub Svoboda, MD, Eline T. Luning Prak, MD,PhD, Stephen J. Schuster, MD, Patricia Tsao, MD PhD, Colleen Dorsey, BSN, RN, Pamela S. Becker, MD, Danielle M. Brander, MD, Sunita Dwivedy Nasta, MD, Daniel J. Landsburg, MD, Cara M King, MPH, Beth Morrigan, Kaitlin Kennard, RN, BSN, Lindsey E. Roeker, MD, Andrew D. Zelenetz, MD PhD, Michelle Purdom, PhDRN, Dana Paskalis, Peter Sportelli, BS, Hari P Miskin, MSc, Michael S. Weiss, Mazyar Shadman, MD MPH
Journal: Blood
Blood (2018) 132 (Supplement 1): 297.
https://doi.org/10.1182/blood-2018-99-117526
Published: 2018
Journal Articles

KI Intolerance Study: A Phase 2 Study to Assess the Safety and Efficacy of Umbralisib (TGR-1202) in Patients with Chronic Lymphocytic Leukemia (CLL) Who Are Intolerant to Prior BTK or PI3K-δ Inhibitor Therapy

Anthony R. Mato, MD, Bruce D. Cheson, MD, Nicole Lamanna, MD, John M. Pagel, MD PhD, Frederick Lansigan, MD, Paul M. Barr, MD, Jeffrey J. Pu, MD PhD, Colleen Dorsey, BSN, RN, Elizabeth T Chatburn, BS, Jakub Svoboda, MD, Stephen J. Schuster, MD, Eline Luning-Prak, MD PhD, Patricia Tsao, MD PhD, Andrea Sitlinger, MD, Chaitra S. Ujjani, MD, Dana Paskalis, Peter Sportelli, BS, Hari P Miskin, MSc, Michael S. Weiss, Danielle M. Brander, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4314.
https://doi.org/10.1182/blood.V130.Suppl_1.4314.4314
Published: 2017
Journal Articles

An Integrated Safety Analysis of the Next Generation PI3Kδ Inhibitor Umbralisib (TGR-1202) in Patients with Relapsed/Refractory Lymphoid Malignancies

Matthew S. Davids, MD, Ian W. Flinn, MD PhD, Anthony R. Mato, MD, Owen A. O'Connor, MD, PhD, Danielle M. Brander, MD, Matthew A. Lunning, DO, Julie M. Vose, MDMBA, Loretta Nastoupil, MD, Nathan Fowler, MD, Christopher Flowers, MD, Jennifer R. Brown, MD PhD, Marshall T. Schreeder, MD, Nilanjan Ghosh, MD PhD, Frederick Lansigan, MD, Bruce D. Cheson, MD, Paul M. Barr, MD, John M. Pagel, MD PhD, Alexey Danilov, MD PhD, Javier Pinilla-Ibarz, MD PhD, Changchun Deng, MD PhD, John M. Burke, MD, Tanya Siddiqi, MD, Manish R Patel, MD, Charles M. Farber, MD PhD, Parameswaran Venugopal, MD, John G. Gribben, MDDSc FMedSci, Pier Luigi Zinzani, MD, Hari P Miskin, MSc, Peter Sportelli, BS, Michael S. Weiss, Susan M. O'Brien, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4037.
https://doi.org/10.1182/blood.V130.Suppl_1.4037.4037
Published: 2017
Journal Articles

Phase I/II Study of Pembrolizumab in Combination with Ublituximab (TG-1101) and Umbralisib (TGR-1202) in Patients with Relapsed/Refractory CLL

Anthony R. Mato, MD, Colleen Dorsey, BSN, RN, Elizabeth T Chatburn, BS, Jessica Geoghegan, Stephen J. Schuster, MD, Jakub Svoboda, MD, Pamela S. Becker, MD PhD, Elise A. Chong, MD, Sunita Dwivedy Nasta, MD, Daniel J. Landsburg, MD, Kaitlin Kennard, RN, BSN, Eline Luning-Prak, MD PhD, Patricia Tsao, MD PhD, Mitchell E. Hughes, PharmD, BCPS, BCOP, Michelle Purdom, PhDRN, Dana Paskalis, Peter Sportelli, BS, Hari P Miskin, MSc, Michael S. Weiss, Mazyar Shadman, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3010.
https://doi.org/10.1182/blood.V130.Suppl_1.3010.3010
Published: 2017
Journal Articles

Preliminary Results from a Phase I Dose Escalation Trial of Ruxolitinib and the PI3Kδ Inhibitor TGR-1202 in Myelofibrosis

Tamara K Moyo, MD PhD, Andrew Sochacki, MD, Gregory D Ayers, MS, Michael T. Byrne, DO, Stephen A. Strickland, Sanjay R. Mohan, MD, Jill Harrison, Lynne D Berry, Channing V Dudley, Rachel Severs, Laura Dugger, Hari P. Miskin, MS, Amy Cavers, Peter Sportelli, Laura C Michaelis, MD, Ruben A. Mesa, MD, Michael R. Savona, MD
Journal: Blood
Blood (2016) 128 (22): 1125.
https://doi.org/10.1182/blood.V128.22.1125.1125
Published: 2016
Journal Articles

TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory CLL or MCL: Preliminary Results of a Multicenter Phase I/Ib Study

Matthew S. Davids, Haesook T. Kim, PhD, Alyssa Nicotra, BA, Alexandra Savell, BS, Karen Francoeur, RN, Jeffrey Hellman, PA-C, Hari P. Miskin, MS, Peter Sportelli, Asad Bashey, MD PhD, Laura Stampleman, MD, Jens Rueter, MD, Adam Boruchov, MD, Jon Arnason, MD, Caron A. Jacobson, MD, David C. Fisher, MD, Jennifer R. Brown
Journal: Blood
Blood (2016) 128 (22): 641.
https://doi.org/10.1182/blood.V128.22.641.641
Published: 2016